Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Most relevant news about GILEAD SCIENCES
05:28pNICE wavers on end of life exception for DLBCL CAR Ts, says Kymriah doesn't m..
AQ
04:33pMANAGEMENT TRACKS : GSK adds Corsico, Enzmann to chair CHMP
AQ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/17GILEAD SCIENCES : and Precision BioSciences Announce Collaboration to Develop Th..
AQ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/14CAR T play Allogene files for IPO
AQ
09/13GILEAD SCIENCES : Andrew Cheng, MD, PhD Joins Akero Therapeutics as President an..
AQ
09/13GILEAD SCIENCES : Precision partner on genome-editing therapies for HBV
AQ
09/13GILEAD SCIENCES : Ex-dividend day for
FA
09/12Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
09/12NASDAQ 100 MOVERS : Mxim, gild
AQ
09/12GILEAD SCIENCES : Precision BioSciences Developing Hepatitis B Therapies
DJ
More most relevant news
All news about GILEAD SCIENCES
08:19pGILEAD SCIENCES : An Application for the Trademark "WILKARTA" Has Been Filed by ..
AQ
05:28pNICE wavers on end of life exception for DLBCL CAR Ts, says Kymriah doesn't m..
AQ
05:24pGILEAD SCIENCES : Investigators from Gilead Sciences Zero in on HIV/AIDS (Drug-D..
AQ
04:33pMANAGEMENT TRACKS : GSK adds Corsico, Enzmann to chair CHMP
AQ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18GILEAD SCIENCES INC : Change in Directors or Principal Officers (form 8-K)
AQ
09/17GILEAD SCIENCES : and Precision BioSciences Announce Collaboration to Develop Th..
AQ
09/15GILEAD SCIENCES : and Precision BioSciences Collaborate to Develop Therapies Aga..
AQ
More news
Sector news : Bio Therapeutic Drugs
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/12EUROPE : European stocks shrug off trade worries as oil stocks rally
RE
09/12Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
09/06Gilead, Galapagos Phase 2 Filgotinib Study Meets Primary Endpoint
DJ
09/04Factbox - Challenges facing German pharmaceutical company Bayer
RE
More sector news : Bio Therapeutic Drugs
Official Publications
09/04Report 
08/28Nomination 
08/14Nomination 
08/10Report 
08/03Report 
08/02Report 
More Official Publications
News from SeekingAlpha
09/19My Quarterly Global Portfolio Update 
09/18AbbVie used kickbacks to boost Humira sales - CA insurance commissioner 
09/18For Investors Seeking Exposure To Biotech, BB Biotech AG Might Be An Interest.. 
09/18GILEAD : Forming A Base? 
09/17Can The Hepatitis B Market Become The Next Growth Story For Gilead Sciences? 
09/17MY ANNIVERSARY : One Year Later, My Articles Outperform The S&P By 50% 
Latest Tweets
03:25pPharmalot.. Pharmalittle.. Good Morning.. Merck to halve Keytruda price in Ch.. 
02:26pGet the latest news and updates for $WTBA $GILD $BIIB $TLAB $KEYN automatical.. 
09/19Gilead faces doubts on Wall Street a year after its $12 billion deal
6
09/19$GILD ALERT: New Gilead Sciences SEC Filing From our Stock News Alerts App
1
09/19U.K. court invalidates Gilead's Truvada patent extension
3
More tweets
Qtime:427
Financials ($)
Sales 2018 21 377 M
EBIT 2018 11 220 M
Net income 2018 6 650 M
Debt 2018 12 363 M
Yield 2018 3,08%
P/E ratio 2018 14,66
P/E ratio 2019 13,48
EV / Sales 2018 5,06x
EV / Sales 2019 4,91x
Capitalization 95 774 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 88,0 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.13%95 774
VERTEX PHARMACEUTICALS18.19%45 132
REGENERON PHARMACEUTICALS3.29%40 728
NEUROCRINE BIOSCIENCES, INC.54.99%10 622
SAREPTA THERAPEUTICS INC173.09%10 096
GENMAB-1.17%9 788